Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Symphogen Announces the Appointment of Annika Espander Jansson

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Appointment of Annika as Non-Executive Director of the Board.

Symphogen A/S has announced the appointment of Annika Espander Jansson as a Non-Executive Director of the Board, with effect from 19 December 2013.

Annika has over twenty years’ experience in the healthcare sector, both as a sell-side analyst and investor. She has a proven track record in strategic development of businesses and broad experience in managing operations in different segments of the financial markets.

Annika began her career as Equity Analyst and Sector Head of Healthcare at Aros Securities in Stockholm 1994-1996, followed by similar roles at Enskilda Securities, where she was Sector Head of Equity Research in Healthcare for five years, and Handelsbanken Capital Markets, where she gained experience of the financial services sector and became Group Head of Private Banking.

She joined Catella Healthcare, a private venture capital investor in healthcare companies, in 2004 as Managing Partner of a small team of professionals, during which time the IRR of the company’s portfolio exceeded 35%.

Annika returned to Handelsbanken as Global Head of Private Banking in September 2010-June 2013 during which time the bank’s ranking was upgraded to No. 1, according to the influential client survey - Prospera.

Annika is currently the founder and CEO of Asperia, a strategic and business advisory firm in the healthcare and financial services sectors. She is also a Board member of the public companies Stille AB and Probi AB, private portfolio companies Attana AB, Cellartis AB and Duocort AB, as well as the Swedish Financial Analyst Organization. Annika holds a Ph.D. from the University of Gothenburg.

Welcoming the appointment, Gôran Ando MD, Chairman of the Board, commented: “I am delighted to welcome Annika to Symphogen. Annika’s extensive experience in both the healthcare industry and financial markets makes her a perfect addition to the Board. Annika’s skills, knowledge and experience will be invaluable to furthering the success of Symphogen.”

Annika Espander Jansson added: “I am very excited to take part in the development of Symphogen which operates in a very important medical area with significant unmet medical needs and with a business concept aiming at improving therapies for cancer patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Symphogen’s Antibody Mixtures Highlighted in Three Peer-Reviewed Journals
Pioneering and novel approach to Anti-EGFR and Pan-HER antibodies validated in clinical and pre-clinical research papers.
Thursday, May 28, 2015
Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration
Payment enhances the financial position of Symphogen.
Wednesday, June 26, 2013
Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!